To evaluate the relationship between ATM gene mutations and the prognosis of bladder cancer patients who received ICI treatment, we collected an immunotherapy cohort with clinical data and mutational data (Samstein et al., 2019). The gene discussed is ATM; the disease is urinary bladder carcinoma.